Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
122 hedge funds and large institutions have $524M invested in Clovis Oncology, Inc. in 2016 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 49 increasing their positions, 29 reducing their positions, and 37 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
8% less call options, than puts
Call options by funds: $13.6M | Put options by funds: $14.8M
10% less funds holding
Funds holding: 135 → 122 (-13)
27% less capital invested
Capital invested by funds: $722M → $524M (-$198M)
32% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$42.9M |
| 2 |
Morgan Stanley
New York
|
+$18.6M |
| 3 |
Goldman Sachs
New York
|
+$10.7M |
| 4 |
SC
Samlyn Capital
New York
|
+$9.92M |
| 5 |
HM
HealthCor Management
New York
|
+$9.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
-$23.9M |
| 2 |
PC
PointState Capital
New York
|
-$20M |
| 3 |
O
OrbiMed
New York
|
-$12.7M |
| 4 |
LPU
Lansdowne Partners (UK)
London,
United Kingdom
|
-$10.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.2M |
CLVS Hedge Fund Activity: Q2 2016 in Review
122 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q2 2016, worth a combined $524M — down 27% from $722M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of CLVS and 25 opened new positions — a net loss of 12 holders — while 29 trimmed existing stakes and 49 added.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $42.9M. The largest seller was OppenheimerFunds, exiting entirely with an estimated $23.9M sold.
- 122 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q2 2016, down from 135 in Q1 2016.
- Funds reported $524M of Clovis Oncology, Inc. stock for Q2 2016, down 27% quarter-over-quarter.
- 25 funds opened new Clovis Oncology, Inc. positions in Q2 2016 and 37 closed out, a net change of -12 holders.
- The largest Clovis Oncology, Inc. buyer in Q2 2016 was Consonance Capital Management, an estimated $42.9M added.
- The largest Clovis Oncology, Inc. seller in Q2 2016 was OppenheimerFunds, an estimated $23.9M sold.
Based on aggregated 13F filings for Q2 2016.